Business Wire

Structure Therapeutics Extends Financing, Advances Diabetes and Obesity Clinical Program and Changes Name from ShouTi

SAN FRANCISCO & SHANGHAI--(BUSINESS WIRE)--Structure Therapeutics Inc. (Structure Therapeutics), formerly known as ShouTi Inc., today announced it closed an oversubscribed $33 million financing round, ...
manilatimes

Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
Hosted on MSN

Structure Therapeutics announces positive clinical trial results

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

Grace Point Treatment Center Releases Educational Resource on Intensive Outpatient Treatment Models

FORT LAUDERDALE, FL - January 13, 2026 - PRESSADVANTAGE - Grace Point Treatment Center in Fort Lauderdale, Florida, has ...
Yahoo Finance

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
Seeking Alpha

Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic ...
Nasdaq

Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Strong financial position with cash, cash equivalents and short-term investments of $786.5 million as of June 30, 2025 expected to fund projected operations and key clinical milestones through at ...